Adynxx (FRA:HL1C) Additional Paid-In Capital : €32.00 Mil(As of Sep. 2019)

View and export this data going back to 1998. Start your Free Trial

What is Adynxx Additional Paid-In Capital?

Adynxx's quarterly additional paid-in capital declined from Mar. 2019 (€147.51 Mil) to Jun. 2019 (€31.12 Mil) but then increased from Jun. 2019 (€31.12 Mil) to Sep. 2019 (€32.00 Mil).

Adynxx's annual additional paid-in capital declined from Dec. 2016 (€148.26 Mil) to Dec. 2017 (€139.99 Mil) but then increased from Dec. 2017 (€139.99 Mil) to Dec. 2018 (€146.51 Mil).

Adynxx Additional Paid-In Capital Historical Data

The historical data trend for Adynxx's Additional Paid-In Capital can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Adynxx Additional Paid-In Capital Chart

Adynxx Annual Data

Trend

Dec09

Dec10

Dec11

Dec12

Dec13

Dec14

Dec15

Dec16

Dec17

Dec18

Additional Paid-In Capital

Get a 7-Day Free Trial

75.05

136.28

148.26

139.99

146.51

Adynxx Quarterly Data
	Dec14	Mar15	Jun15	Sep15	Dec15	Mar16	Jun16	Sep16	Dec16	Mar17	Jun17	Sep17	Dec17	Mar18	Jun18	Sep18	Dec18	Mar19	Jun19	Sep19
Additional Paid-In Capital	Get a 7-Day Free Trial															142.84	146.51	147.51	31.12	32.00

Adynxx Additional Paid-In Capital Calculation

Capital that a company raises in a financing round in excess of the capital's par value. The account represents the excess paid by an investor over the par-value price of a stock issue. Additional paid-in-capital can arise from issuing either preferred or common stock.

Additional Paid-In Capital is calculated as

Additional Paid-In Capital

(Issue Price

Par Value)

Shares Outstanding (Diluted Average)

Adynxx Additional Paid-In Capital Related Terms

Thank you for viewing the detailed overview of Adynxx's Additional Paid-In Capital provided by GuruFocus.com. Please click on the following links to see related term pages.

Adynxx (FRA:HL1C) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Adynxx Inc (FRA:HL1C) » Definitions » Additional Paid-In Capital

Comparable Companies

Traded in Other Exchanges

N/A

Address

100 Pine Street, Suite 500, San Francisco, CA, USA, 94111

Website

http://www.adynxx.com

Adynxx Inc is a United States-based clinical-stage biopharmaceutical company. It is focused on the development of a new class of therapeutics called transcription factor decoys and bringing to the market novel, disease-modifying products to address unmet needs in the treatment of pain and inflammation. Its pipeline includes brivoligide, a Phase 2 drug candidate intended to address postoperative pain, and AYX2, a pre-clinical candidate intended to treat chronic syndromes of pain, including both inflammatory and neuropathic pain.

Adynxx (FRA:HL1C) Headlines

No Headlines